We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Docetaxel for platinum-refractory advanced thymic carcinoma.
- Authors
Naohiro Watanabe; Shigeki Umemura; Seiji Niho; Keisuke Kirita; Shingo Matsumoto; Kiyotaka Yoh; Hironobu Ohmatsu; Koichi Goto
- Abstract
Objective: Thymic carcinoma is a rare mediastinal neoplasm. While platinum-based chemotherapy has been reported to be effective for advanced thymic carcinomain a first-line setting, little information is available regarding the benefits of salvage chemotherapy for platinum-refractory thymic carcinoma. This study assessed the efficacy and safety profiles of docetaxel monotherapy for platinum-refractory thymic carcinoma. Methods: A total of 13 thymic carcinoma patients treated with docetaxelmonotherapy in a second- or later-line setting between January 2003 and April 2014 were retrospectively reviewed. The median age was 61 years (range, 41-75 years). Results: The overall response rate and disease control rate were 31% [95% confidence interval (CI), 6-56%] and 77% (95% CI, 54-100%), respectively. The median progression-free survival and overall survival after docetaxel monotherapy were 5.5 months (95% CI, 2.3-6.5 months) and 24.0 months (95% CI, 9.4-31.2 months), respectively. The most common Grade ≥3 toxicity was neutropenia (62%). No incidents of febrile neutropenia and no treatment-related deaths were recorded. Conclusions: This retrospective analysis demonstrated that docetaxel was active against platinumrefractory thymic carcinoma with acceptable toxicities. Docetaxel monotherapy might be a promising therapeutic option for patients with platinum-refractory thymic carcinoma.
- Publication
Japanese Journal of Clinical Oncology, 2015, Vol 45, Issue 7, p665
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyv046